Screener
Zymeworks ZYME Other drug supply — Research and development collaborations
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| BeOne: | ||||
| Milestone revenue | — | 20,000 | — | 20,000 |
| Recognition of deferred revenue | — | 18,334 | — | 18,334 |
| Drug supply | 1,664 | 7 | 1,664 | 215 |
| Royalties | 210 | 19 | 434 | 19 |
| Bristol-Myers Squibb company, (“BMS”): | ||||
| Option exercise fee | — | 7,500 | — | 7,500 |
| GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”): |
Item 1. Financial Statements
FAQ
- What is Zymeworks's other drug supply — research and development collaborations?
- Zymeworks (ZYME) reported other drug supply — research and development collaborations of $1.66M in Q2 2026.
- How has Zymeworks's other drug supply — research and development collaborations changed year-over-year?
- Zymeworks's other drug supply — research and development collaborations increased by 23671.4% year-over-year, from $7K to $1.66M.
- What does other drug supply — research and development collaborations mean?
- This metric represents revenue recognized from research and development collaboration agreements specifically associated with the company's drug supply or platform service offerings. It reflects the financial value derived from partnerships where the company provides specialized biotherapeutic development capabilities or clinical supply support to third-party collaborators. Tracking this revenue stream helps investors assess the commercial viability of the company's proprietary technology platforms and the strength of its strategic partnership model.
Ask your AI about Zymeworks's other drug supply — research and development collaborations.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude